Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4099 results

Sort By:

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Study ID: NCT07456826
Start Date: 2026-04
End Date: 2026-08
Study Type

Interventional

Study Phase

Phase4

No. of Participants

236

Intervention / Treatment

Chloroprocaine Ophthalmic Gel 3% (IHEEZO)

Sham Subconjunctival Injection

Proparacaine Hydrochloride Ophthalmic Solution 0.5%

Lidocaine Hydrochloride Injection 2%

Sponsor

Harrow Inc

Source: clinicaltrials.gov

Share:
Add to list

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Study ID: NCT07416474
Start Date: 2026-03-31
End Date: 2029-11-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

574

Intervention / Treatment

RC148 plus Carboplatin and Paclitaxel

Tislelizumab plus Carboplatin and Paclitaxel

Sponsor

RemeGen Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation

Study ID: NCT07445789
Start Date: 2026-06
End Date: 2029-06
Study Type

Interventional

Study Phase

Phase4

No. of Participants

436

Intervention / Treatment

Verapamil 240 mg slow-release tablet

metoprolol 100 mg slow-release tablet

Sponsor

Martini Hospital Groningen

Source: clinicaltrials.gov

Share:
Add to list

Innovating Technology Solutions for Residents in Support Housing Communities w SUD Through Community-Engaged Research

Study ID: NCT07001020
Start Date: 2026-04-01
End Date: 2026-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

25

Intervention / Treatment

Technology-based Intervention

Sponsor

Oregon Research Behavioral Intervention Strategies, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.

Study ID: NCT07484633
Start Date: 2026-04
End Date: 2028-04
Study Type

Interventional

Study Phase

Phase4

No. of Participants

110

Intervention / Treatment

Extended infusion time of beta-lactams (meropenem, piperacillin/tazobactam, cefepime, ceftriaxone)

Short-term infusion time of beta-lactams (meropenem, piperacillin/tazobactam, cefepime, ceftriaxone)

Sponsor

Semmelweis University

Source: clinicaltrials.gov

Share:
Add to list

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Study ID: NCT06600880
Start Date: 2026-08
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

6

Intervention / Treatment

Neuronavigation-guided single-element focused ultrasound transducer

Lumason

Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents

Positron Emission Tomography (PET)

Amyvid

MK-6240

dotaram

Blood draw

UR5e

Urine test

Sponsor

Columbia University

Source: clinicaltrials.gov

Share:
Add to list

Older Age and Generalization

Study ID: NCT07440017
Start Date: 2026-06-01
End Date: 2029-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

360

Intervention / Treatment

Memory decision type

Sponsor

Caitlin Bowman

Source: clinicaltrials.gov

Share:
Add to list

Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer

Study ID: NCT07468838
Start Date: 2026-05
End Date: 2027-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

25

Intervention / Treatment
Sponsor

Western Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Study ID: NCT07438626
Start Date: 2026-06-01
End Date: 2030-02-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Sacituzumab tirumotecan

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.

Study ID: NCT07398508
Start Date: 2026-06-01
End Date: 2030-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

6

Intervention / Treatment

Droxidopa Oral Product

Placebo Control

Sponsor

Stephen G. Kaler

Source: clinicaltrials.gov

Share:
Add to list